Hoag Memorial Hospital Presbyterian | ClinicalTrials HQ

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma	Adnexal Diseases, Cancer of Gastrointestinal Tract, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast cancer, breast disorder, breast neoplasm, carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, hepatocellular carcinoma, kidney cancer, kidney disorder, liver disorder, lung cancer, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, prostate cancer, prostate disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, transitional cell carcinoma, urinary system disorder, urothelial carcinoma	Recruiting	Phase 1	2026-08-27		NCT06582017
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	Insulin Resistance, Neoplasms by Site, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, glucose metabolism disease, hyperglycemia, hyperinsulinism, metabolic disease, neoplasm, skin disorder	Recruiting	Phase 1 / Phase 2	2026-04-22		NCT05455619